Enhancing the Awareness of the Local Risk Management Plan for Strontium Ranelate (Protos®) to Mitigate the Risk of Serious Skin Reactions

HSA would like to inform healthcare professionals that with effect from 1 January 2014, as part of a new licensing condition to the company, Servier will have to obtain the signed acknowledgement from doctors that they are aware of the risk management plan for strontium ranelate (Protos^®) to mitigate the risk of serious skin reactions, and that they have received the patient medication guide for distribution to their patients before the company can supply strontium ranelate to the respective clinics and hospitals. This requirement is made to further enhance the awareness of serious skin reactions associated with strontium ranelate among healthcare professionals and patients and to mitigate these risks through close monitoring and early detection of these reactions. Please refer to the letter for more details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.